Advancing evidence-based mental health

Research from the Osmind platform is already helping to set new standards for mental health interventions. See how the academic, life sciences, regulatory, and patient advocacy communities can apply real-world evidence to safely speed advances in mental health care at this critical time.

Doctor treating patient at his office
Colorful pathway of Osmind's branding

Our team includes leading mental health and neuroscience researchers

Stanford Medicine logo
Massachusetts General Hospital logo
University of California San Francisco logo
UC San Diego School of Medicine logo

“Real-world evidence data collection is taking off in the ketamine space, and it's clear Osmind are field leaders here. I look forward to seeing real-world evidence initiatives being utilized when MDMA and psilocybin therapy become available for patients. It will be essential for assessing their relative merits versus already existing treatment options, including ketamine infusion therapy.”

Robin Carhart-Harris, PhD

Ralph Metzner Distinguished Professor of Neurology and Psychiatry and Founding Director of the Neuroscape Psychedelics Division, UCSF

Osmind Real-World Outcomes Research

Osmind, in concert with the global research community, has facilitated some of the most extensive real-world studies on ketamine infusion therapy (KIT) to treat depression, anxiety, and suicidality. These studies aspire to assess long-term patient outcomes and provide an in-depth understanding of the efficacy and safety of KIT in real-world settings.

Our inaugural study, McInnes et al. 2022, was published in the Journal of Affective Disorders. Pioneered by Dr. Alison McInnes, Osmind's VP of Scientific Affairs, McInnes et al. 2022 yielded promising results: Ketamine emerged as an effective and lasting treatment for depression, with a robust effect size of 1.5 and over 70% of patients demonstrating improvement in suicidal ideation at baseline.

Building on, Hietamies et al. 2023 conducted an independent replication of the first study in a larger sample size, this time including anxiety outcomes data. This study involved faculty researchers from Heifets Lab at Stanford University, with significant contributions from Dr. Alison McInnes, VP of Scientific Affairs at Osmind. The study assessed how dosage, comorbid anxiety, and maintenance treatment impact depression outcomes.

The study replicated the findings from McInnes et al. 2022 on reduction in depression symptoms and suicidal ideation; More than half of the patients experienced a 50% reduction in depression and anxiety symptoms. Furthermore, of the 80% of patients who reported suicidal ideation before treatment, an impressive 70% experienced improvement, with half experiencing no suicidal ideation at all after treatment.

We also identified a group of late responders (20%) who experienced a response by infusions 10-12 , rather than after the usual six-infusion induction protocol, corroborating the findings of Oliver et al. 2022.

Combined, these studies demonstrate that response to ketamine is stable over time, and its antidepressant and anti-anxiety effects do not significantly diminish with repeated treatments.

The power of real-world studies is their ability to strengthen the case for KIT's efficacy. Clinical trials usually examine a specific set of controlled parameters, whereas real-world scenarios involve diverse treatment regimens and patient characteristics—which better reflects the complex nature of treatment-resistant depression.

By collaborating with dedicated clinicians and researchers, Osmind is leading the way in understanding and advancing innovative treatment options. Studies of this magnitude are essential to overcoming barriers to care, including availability through therapeutic development, psychiatrist adoption, and affordability through insurance coverage.

Additional selected research activities

We're focused on enabling cutting-edge research and advancing therapeutics, precision diagnostics, and care management programs.

Fluence logo

Embracing Pragmatism for Ketamine Insurance Coverage: Leveraging Real-World Evidence

Towards the end of 2023, a group of clinician-researchers from the National Network of Depression Centers issued an appeal to payers to provide insurance coverage for ketamine infusion therapy (Niciu et al. 2023).

Read Announcement

Fluence logo

Largest Real-World Study on Effectiveness of Ketamine Intravenous Therapy for Depression, Anxiety and Suicidal Ideation

Peer-reviewed analysis reveals improvements in depression and anxiety in more than half of patients and 70% for those with suicidal ideation.

Read Announcement

Fluence logo

Using a Longitudinal Model to Predict Outcomes to Ketamine Intravenous Therapy for Depression

Ketamine Intravenous Therapy (KIT) is an effective, rapid-acting treatment for depression, but individual patients’ responses may be highly variable over time.

Learn more

Ketamine Taskforce for Access to Safe Care and Insurance coverage logo

Prediction of Treatment Adherence to Ketamine Infusion Therapy

Ketamine Infusion Therapy (KIT) can be highly effective for treatment resistant depression, but poor adherence can undermine its efficacy for many patients.

Learn more

Fluence logo

Psychedelic Integration Study

With our partner Fluence, we have launched a prospective observational study on psychedelic harm reduction and integration in naturalistic care settings. Please see the study website for more information.

Visit Fluence

Ketamine Taskforce for Access to Safe Care and Insurance coverage logo

Ketamine-mediated improvement of daily living

In collaboration with the Ketamine Taskforce for Access to Safe Care and Insurance Coverage, we are conducting a prospective study on how ketamine affects activities of daily living and other functional outcomes in CRPS patients.

Visit Ketamine Task Force

Help bring more breakthroughs to mental health

Join our team supporting clinicians and researchers advancing life-saving new treatments for people living with mental health conditions.

Company team chatting at an informal reunion

If you, or someone you know, is in crisis or needs immediate assistance, please call 911 immediately. To talk to someone now, please call the National Suicide Prevention Lifeline at 1-800-273-8255.

Osmind Inc. © 2024 All Rights Reserved.